Comment Period Closes on May 31, 2019 at 5 pm ET.
Drug Concentration standardization represents a core set of actions that protect patients and focus on developing the fewest number of drug concentrations to provide safe clinical care. Reduction of variance in concentrations in an effort to decrease medication errors is the goal of the drug concentration standardization effort.
Standardization may include a limited, set of concentrations for medications that have been labeled as high-alert or known to have produced a significant number of adverse events.
Facilities may seek to harmonize such concentrations with local stakeholders and within their drug libraries and balance the objective of reducing the risk of patient harm with pragmatic considerations, such as strength and quality of evidence, feasibility and economic burden.
The drug concentrations linked below and available for comment were discussed and created by a workgroup of physician anesthesiologists led by the American Society of Anesthesiologists Committee on Quality Management & Departmental Administration (QMDA). The dosages were identified using available manufacturer dosages, completing a literature and ASA closed claims review, common usage among workgroup members and local drug libraries. Drugs listed in the linked tables are ordered alphabetically and do not indicate higher or lower risk based upon the order displayed.
ASA invites comments from ASA members, interested persons and professional societies/organizations on the proposed concentrations. All comments will be kept confidential and evaluated by the workgroup and QMDA members. ASA Members and the public should submit comments by completing this online form.
For questions, please contact that ASA Department of Quality and Regulatory Affairs at firstname.lastname@example.org.
This committee work product has not been approved by ASA's Board of Directors or House of Delegates and does not represent an ASA Policy, Statement or Guideline.